单抗类药物治疗多发性硬化的研究进展  

Research progress of monoclonal antibodies in treatment of multiple sclerosis

作　　者：张熙晗 邵华[1,2] 厉伟兰[1,2] 牛一民 ZHANG Xi-han;SHAO Hua;LI Wei-lan;NIU Yi-min(School of Medicine,Southeast University,Nanjing JIANGSU 210009,China;Department of Pharmacy,Zhongda Hospital Southeast University,Nanjing JIANGSU 210009,China)

机构地区：[1]东南大学医学院,江苏南京210009 [2]东南大学附属中大医院药学部,江苏南京210009

出　　处：《中国新药与临床杂志》2023年第12期781-786,共6页Chinese Journal of New Drugs and Clinical Remedies

基　　金：江苏省药学会奥赛康医院药学科研基金(A202210);国家自然科学基金(81901863)。

摘　　要：多发性硬化(multiple sclerosis,MS)是一种免疫介导的中枢神经系统慢性炎性脱髓鞘性疾病。适应性免疫系统以及伴随的中枢神经系统炎症级联反应被认为在MS发病过程中发挥重要作用。单抗类药物具有特异靶向性,可精准作用于靶细胞或分子而阻碍MS发展进程。本文结合MS发生的免疫学机制,重点综述基于α4整合素拮抗、抗CD52、靶向白细胞介素-2受体α亚基CD25、抗CD20等机制的单抗类药物在治疗MS方面的研究进展。Multiple sclerosis(MS)is an immune-mediated chronic inflammatory demyelinating disease of the central nervous system(CNS).It is believed that the adaptive immune system and the accompanying inflammatory cascade response in the CNS play an important role in the pathogenesis of MS.Monoclonal antibodies specifically act on target cells or molecules to impede the process of MS development.This paper focuses on the research progress of monoclonal antibody analogs based on the mechanisms ofα4 integrin antagonism,ANTI-CD52,targeting IL-2 receptorαsubunit CD25,and ANTI-CD20 in the treatment of MS in combination with the immunological mechanisms of MS development.

关 键 词：脱髓鞘自身免疫疾病 中枢神经 多发性硬化 抗体 单克隆 药物疗法 

分 类 号：R979.5[医药卫生—药品]